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The role of endogenous oxytocin as neuromodulator of birth, lactation and social behaviors
is well-recognized. Moreover, the use of oxytocin as a facilitator of social and other
behaviors is becoming more and more accepted. Many positive effects have been
attributed to intranasal oxytocin administration in animals and humans; with current
research highlighting encouraging advances in its potential for use in mental health
disorders. The new frontier will be investigating the effective use of oxytocin in pediatric
populations. Limited animal data is available on this. Large-scale human studies focusing
on autism are currently under way, but many other possibilities seem to lie in the
future. However, we need to know more about the risks and effects of repeated use
on the developing brain and body. This paper will provide an overview of the current
understanding of the role of endogenous oxytocin and its related neuropeptide systems in
influencing behaviors, in particular attachment, and will review (a) the literature on the use
of intranasal oxytocin in young animals, children (age range birth-12 years) and adolescents
(age range 13–19 years), (b) the expected benefits and risks based on the current research,
and (c) the risks of oxytocin in children with severe psychopathology and early life trauma.
The paper will conclude with a clinical perspective on these findings.
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INTRODUCTION
Current understanding of oxytocin and its related neuropeptide
systems is growing at an exponential rate. Oxytocin’s centrally
acting role in behavioral modulation and attachment is increas-
ingly recognized (Feldman, 2012; Churchland and Winkielman,
2012; Tops et al., 2014). Recent studies (Broadbear et al., 2014;
Love, 2014; Tops et al., 2014) have been able to highlight a
neurobiological model for these behavioral changes, and outline
with greater specificity the complex interaction between oxy-
tocin and other neuropeptides and monoamines. These findings
have been applied and expanded to the field of addiction, and
behavioral neuroscience (Kovacs et al., 1998; Rilling et al., 2012;
Buisman-Pijlman et al., 2014b; Williams and Johns, 2014; Zanos
et al., 2014). Many positive effects have now been attributed to
intranasal oxytocin in the adult population (Veening and Olivier,
2013), however there are multiple questions that remain unan-
swered in regards to the safe and effective use of intranasal
oxytocin in the child and adolescent population. In particular,
there is a lack of evidence in regards to the effects of both acute
and chronic exposure on the developing brain. This paper aims
to provide a review of current knowledge in relation to this area,
and highlight both theoretical and clinical gaps in research evi-
dence and data regarding what will likely be an increasing area of
interest in themanagement of common childhood and adolescent
psychiatric disorders in future.
This paper will briefly review the current understanding of
the role of endogenous oxytocin and its related neuropeptide sys-
tems in influencing behaviors, in particular attachment, and will
review (a) the literature on the use of intranasal oxytocin in young
animals, infants, children and adolescents, (b) the expected ben-
efits and risks based on the current research, and (c) the risks
of oxytocin in children with severe psychopathology and early
life trauma. Finally this paper aims to utilize the current knowl-
edge base to assist in providing a framework for the direction of
potential further clinical application and will provide examples
for future research questions.
OXYTOCIN AND ITS RELATED NEUROPEPTIDE SYSTEMS
Oxytocin, a hormone synthesized by the hypothalamus and
subsequently secreted by the posterior pituitary gland, is a
neuropeptide well-known for its neuro-modulatory role in lacta-
tion, child-birth, mother-infant bonding (Love, 2014), and more
recently for its role in social affiliation and partner attachment
in adults (Buisman-Pijlman et al., 2014b; Tops et al., 2014).
Oxytocin’s centrally acting effects form the basis of research stem-
ming from Nobel laureate in Chemistry Vincent du Vigneaud’s
early descriptions and syntheses of oxytocin and vasopressin
in 1953 (Love, 2014; Sarnyai and Kovacs, 2014). Oxytocin has
it’s effect through the Oxytocin receptor and Vasopressin 1A
Receptor. Immunohistochemical studies have revealed that mag-
nocellular oxytocin neurons of paraventricular, supraoptic, and
accessory hypothalamic nuclei via local dendritic and distant
axonal release of oxytocin modulate various forms of behaviors
(Lee et al., 2009; Knobloch et al., 2012; Dolen et al., 2013). It
is possible that axonal projections of oxytocin neurons can be
altered in patients afflicted with neurodevelopmental diseases,
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which may impair oxytocin signaling and contribute to defects
in social behavior. Such pathophysiological mechanisms require
further research.
Oxytocin has been shown to have a relationship with both
vasopressin and serotonergic neural pathways (Broadbear et al.,
2014), with increasing evidence suggesting that oxytocin and
vasopressin’s individual and combined modulatory influences on
related neurotransmitter systems, including dopaminergic, sero-
tonergic, and endogenous opioid system play a crucial role in
the brain’s motivational and reward pathways (Love, 2014), and
behaviors related to stress-responses and addiction (Buisman-
Pijlman et al., 2014b; Tops et al., 2014). Oxytocin has also been
implicated in modulating the reactivity of the hypothalamic-
pituitary-adrenal axis (Buisman-Pijlman et al., 2014b), thus in
part determining the extent of psychological and physiological
response to stress (Feldman, 2012).
This expanding knowledge base has underpinned adult human
and animal studies administrating intranasal oxytocin as a mod-
ulator of behaviors, for example, those associated with sub-
stance abuse (McGregor and Bowen, 2012; Pedersen et al., 2013).
Authors have outlined the rationale for intranasal administra-
tion of oxytocin in research, based on this administration route
bypassing the blood-brain barrier, and increasing the half-life of
the delivered substance in cerebrospinal fluid thus ensuring max-
imization of centrally acting effects (Veening and Olivier, 2013).
Intranasal delivery accesses rostral and possibly other brain areas
following absorption through the nasal epithelium (Veening and
Olivier, 2013). In the pediatric population, intranasal delivery of
oxytocin is likely to be the easiest, least intrusive and most prefer-
able mode of administration given pragmatic factors relating to
level of insight into treatment, and aversion behaviors, however
this needs further investigation.
From a clinical perspective, Intellectual Disabilities, Autism
Spectrum Disorders (ASDs) and ADHD are common neurode-
velopmental disorders presenting in childhood. Whilst neurode-
velopmental disorders frequently require ongoing treatment and
management in adolescent populations, this is an age group in
which affective disorders, anxiety disorders and eating disorders,
or traits thereof, also start to manifest and may require clinical
intervention. In the child and adolescent this cohort, disorders
are frequently and universally, however not exclusively, under-
pinned by a developmental history characterized by attachment
difficulties or early life trauma.
OXYTOCIN’S ROLE IN ATTACHMENT
An important precursor to the investigation of oxytocin’s role
within pediatric populations is the concept of attachment. From
a theoretical perspective, Bowlby defines attachment as “a bio-
logical instinct...Attachment behavior anticipates a response by
the attachment figure which will remove threat or discomfort”
(Bowlby, 1960). Oxytocin has been implicated in priming the
bond between a mother and child (Love, 2014), and it is known
from animal studies that the development of the oxytocin system
continues throughout the postnatal period in an experience-
dependent manner (Oreland et al., 2010). Given that develop-
ment of secure attachment is in part reliant on an infant’s salience
toward their primary caregiver, evidence that administration of
oxytocin improves the salience of social cues further highlights
the importance of oxytocin in the process of attachment (Love,
2014; Tops et al., 2014).
VARIATIONS IN THE OXYTOCIN SYSTEM
Notably, findings from animal and human studies display that
there are individual variations within basal oxytocin levels and
in reactivity of the system. Whilst genetics contribute in part,
environmental influences such as social experiences, stress and
trauma early in life have also been shown to affect this variation.
Buisman-Pijlman et al. (2014b) outlined that these influences
can induce long-term changes to the oxytocin system, having
a subsequent impact on an individual’s susceptibility to addic-
tion and relapse. Feldman (2012) also noted that the human
oxytocin system is sensitive to both positive early social experi-
ences and negative experiences such as separation. Rather than a
static feedback system, it is now more accepted through recent
studies that the human oxytocin system functions in a com-
plex context-dependent manner (Feldman, 2012; Guastella and
Macleod, 2012). Factors aside from genetic influence that have
been implicated in variations in an individual’s oxytocin sys-
tem include prenatal maternal stress and substance use (Johns
et al., 1998), early life trauma including parental separation
(Opacka-Juffry and Mohiyeddini, 2012), and childhood sexual
abuse (Heim et al., 2009). A sound understanding of these factors
will be of importance to assess the risks and benefits of exogenous
oxytocin in the pediatric population.
CURRENT EVIDENCE ON THE USE OF INTRANASAL
OXYTOCIN IN YOUNG ANIMALS, INFANTS, CHILDREN, AND
ADOLESCENTS
In the adult population, literature on the use of intranasal oxy-
tocin has spanned the last six decades in research, with early
reports focusing on its role in obstetrics (Hendricks and Pose,
1961; Cohen et al., 1962), followed by exploration of oxytocin’s
possible application to the field of psychiatry, in particular,
obsessive compulsive disorder (Ansseau et al., 1987; Den Boer
and Westenberg, 1992) and symptoms of post-traumatic stress
disorder (Pitman et al., 1993; Olff, 2012).
In the last 10 years, authors have highlighted oxytocin’s proso-
cial effects in the adult population, categorized further into
“trust” (Baumgartner et al., 2008), “mind-reading” and “face-
processing and memory” (Heinrichs et al., 2003; Beetz et al.,
2012) and stress-response in animals (Parker et al., 2005). It is
these benefits, in addition to genetic studies displaying a consis-
tent pattern of oxytocin involvement in ASDs (Campbell et al.,
2011), that have led to an interest in the promise of treatment
of ASDs with intranasal oxytocin. A recent systematic review of
randomized control trials of oxytocin intervention in autism by
Preti et al., noted that whilst promising findings in the measures
of emotion recognition and eye gaze, there is need for better pow-
ered studies prior to valid clinical recommendations being made
(Preti et al., 2014).
Prior to recent years, animal studies relating to the effects
of oxytocin have mainly focused on single dose administra-
tion, and in an adult population. On review of current animal
data (Table 1), there were four studies identified investigating
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administration of oxytocin via intraperitoneal injection, and
three studies using intranasal oxytocin in young.
Studies focusing on intraperitoneal oxytocin injection rein-
forced inconsistent findings displayed in earlier data according
to dose and measured outcome variable, and further highlighted
that in the short-term, oxytocin administration may lead to a
decrease in positive social behaviors (Suraev et al., 2014), whilst
in the long term contribute to heightened social interaction and
diminished display of anxiety (Bowen et al., 2011) (see Table 1).
All three animal studies investigating intranasal oxytocin
involved repeated dosing. Firstly, Bales et al., found repeated
dosing during adolescence had long-term effects on partner pref-
erence in prairie voles (Bales et al., 2013). Secondly, Rault et al.,
found that neonatal pigs displayed increased aggressive behaviors
and locomotion, and diminished social contact following daily
intranasal oxytocin administration in days 1–3 of life. In addition,
there was decreased responsiveness on dexamethasone suppres-
sion test at 11 weeks, suggesting repeated intranasal oxytocin
administration in early life can cause chronic dysregulation of
the hypothalamic-pituitary axis (Rault et al., 2013). Most recently,
Simpson et al., found that in newborn rhesus monkeys, adminis-
tration of daily intranasal oxytocin increased an infant’s affiliative
communication gestures and decreased salivary cortisol levels
(Simpson et al., 2014). In a similar trend identified in the adminis-
tration of oxytocin via intraperitoneal injection in young animals,
the use of intranasal oxytocin produced largely variable results,
which appeared to be dose-dependent. Whilst prosocial effects
and a decrease in salivary cortisol levels were some of the pos-
itive outcomes observed, authors also commented on intranasal
oxytocin administration in young animals having the potential to
increase aggressive behaviors, impair pair-bond formation, and
lead to disruption of the HPA-axis.
A thorough review of current literature found that there were
only six human studies (Table 2) focusing on the use of intranasal
oxytocin in a child or adolescent population. Of these studies,
five occurred in populations with a diagnosis of ASDs (Guastella
et al., 2010; Gordon et al., 2013; Tachibana et al., 2013; Dadds
et al., 2014; Guastella et al., 2014), and one in a population
with Fragile X Syndrome (Hall et al., 2012). Of these six studies,
Guastella et al.’s (2014) RCT investigating the effects of a course
of intranasal oxytocin on social behaviors in youths with ASDs,
and Tachibana et al., were the only groups to investigate chronic
administration of intranasal oxytocin over 2, and 6 month peri-
ods, respectively, although there was notably a small sample size in
the later study. Moreover, only three of the relevant studies found
on review included children under the age of 12 (Gordon et al.;
Dadds et al.; Tachibana et al.), with a clear lack of data pertaining
to the effect of intranasal oxytocin administration in the neonatal
and early childhood/pre-pubertal stages of development, a time
during which the oxytocin system displays its highest degree of
neuroplasticity. From a broader perspective, review of the cur-
rent literature of intranasal oxytocin use in child and adolescent
populations highlighted significant limitations to inferring clin-
ically significant results, and recognizing consistent patterns of
effect between studies, including: small sample sizes, limited data
on chronic use compared to single-dose administration, and a
predilection toward male subjects.
Studies identifying beneficial clinical outcomes to intranasal
oxytocin administration were (1) Gordon et al., who found
improved performance in detecting socially salient information
on a well-validated fMRI emotion judgment task (“Reading the
Mind in the Eyes Test”) following intranasal oxytocin, in addi-
tion to identifying that oxytocin enhances activity in social brain
regions (see Table 2) (Gordon et al., 2013), (2) Guastella et al.,
in their 2010 crossover study who displayed improved perfor-
mance on the RMET in 60% of subjects following intranasal
oxytocin administration (Guastella et al., 2010), (3) Hall et al.,
who reported improved frequency of eye gaze at a specific dose
oxytocin, in addition to decreased salivary cortisol levels in sub-
jects receiving a specific dose (Hall et al., 2012) and (4) Tachibana
et al.,’s study revealing six of a total 8 male youths with a primary
diagnosis of ASD displayed improved performance on communi-
cation and social interaction domains of the Autism Diagnostic
Observation Schedule-Generic (ADOS-G) following incremental
dose increases of intranasal oxytocin over a 6 month period (see
Table 2).
The most recent studies by Dadds et al., and Guastella et al.,
do not report identified significant clinical benefit following the
administration of oxytocin.
Despite an evolving scope of current animal and human
research data relating to the use of intranasal oxytocin in adults,
studies relevant to young animals, and the pediatric popula-
tion remain limited to date. Factors contributing to this may
be related the uncertainty of risks of single, or multiple oxy-
tocin dose administrations on the developing brain, in addition
to an absence of clear methods to measure outcome (Miller et al.,
2013). Review highlighted no significant reporting of side effects
or adverse events in the studied populations, withmultiple studies
referring to intranasal oxytocin being well-tolerated.
THE EXPECTED BENEFITS AND RISKS OF INTRANASAL
OXYTOCIN IN PEDIATRIC POPULATIONS
In assessing expected risks and benefits of oxytocin administra-
tion in the pediatric population, it will be important to first
consider basic principles of neuroadaptation, including the devel-
opment of tolerance, changes in receptor numbers, and receptor
sensitivity, related to repeated exposure of any drug.
Based on current research data in adult animal and human
populations, and the promising findings noted in behavioral
modulation (Miller, 2013; Love, 2014), translational studies to the
pediatric population could too hold promise. There is a poten-
tially broad scope of application for the use of intranasal oxytocin
based on mental health disorders or presentations that are char-
acterized by a decreased responsiveness to social cues, emotional
dysregulation and aggression. It would also be of interest to deter-
mine if the positive findings in the field of oxytocin and substance
addiction (Bowen et al., 2011; Buisman-Pijlman et al., 2014a)
were reproducible in younger populations.
As outlined by Miller et al. (2013) in their study reviewing the
role of gender in regards to symptomatology in ASDs, there are
variations in oxytocin and vasopressin identified between sexes
(Miller et al., 2013). Broader application of this principle and
an understanding of baseline variations in endogenous oxytocin
levels between sexes will likely be important in future research
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involving administration of intranasal oxytocin to both young
males and females for various mental health disorders.
In recent reviews, authors have commented on “cascad-
ing effects” of intranasal oxytocin (Veening and Olivier, 2013)
whereby administration of intranasal oxytocin also stimulates
release of peripherally acting oxytocin (Veening and Olivier,
2013). One rat study did report increased basal levels of oxy-
tocin after long-term administration during adolescence (Suraev
et al., 2014); the opposite could be possible as well-depending
on the age of exposure. Potentially detrimental effects of inad-
vertently raising systemic levels of oxytocin remain unclear both
in the adult and pediatric population, and would require further
investigation from a safety perspective.
RISKS OF OXYTOCIN IN CHILDRENWITH SEVERE
PSYCHOPATHOLOGY AND EARLY LIFE TRAUMA
As outlined, the oxytocin neuropeptide system in humans
remains in an evolutionary state with ongoing plasticity through-
out infancy, early childhood, and during adolescence (Buisman-
Pijlman et al., 2014b).
Those impacted by significant early life trauma are more
likely to display a heightened degree of emotional dysregulation
(Antoniadis et al., 2012). It is well-recognized in psychiatric prac-
tice that emotional dysregulation, impulsivity, and relationship
instability are clinical features of psychopathology in Borderline
Personality Disorder that are likely to be in an evolutionary state
during adolescence (Barnow et al., 2012). The role of oxytocin
in modulating the relational capacities in children and adoles-
cents has been considered extensively in the literature, particular
in relation to attachment disorders, anxiety and autism-spectrum
disorders (Meyer-Lindenberg et al., 2011; Frijling et al., 2014).
The effect of intranasal oxytocin on these subjects might be
difficult to predict. In addition, there will need to be a heightened
awareness of the interconnectivity of for example the dopaminer-
gic, serotonergic, and noradrenergic systems (Tops et al., 2014),
and potential effects this poses, with oxytocin administration. In
a clinical subgroup already plagued by attachment and relational
difficulties, further concern is warranted given the risk of oxytocin
administration leading to long-lasting behavioral and social, and
neuroendocrine consequences (Miller, 2013).
The current research in fact suggests that oxytocin admin-
istration (intranasally) in the clinical settings for autism, social
anxiety disorder, post-natal depression, obsessive-compulsive dis-
order, schizophrenia, borderline personality disorder, and post-
traumatic stress disorder, yield minimal improvement in emotion
recognition and interpersonal trust. In the context of develop-
mental trauma, positive effects (behaviorally or neurobiologi-
cally) were in fact lowered or absent (Bakermans-Kranenburg
and Van IJzendoorn, 2013). It may be more feasible to identify
improvements in disorders that have a homogenous etiology and
little comorbidity.
DISCUSSION
An evolving wealth of animal and human data relating to the
neuro-modulatory role of the endogenous oxytocin system, its
interactions with other neural pathways, and its implications on
behaviors from a neuroscience perspective is expanding at an
exponential rate (Tops et al., 2014). There is evidence highlight-
ing (1) the importance of oxytocin in attachment (Love, 2014)
and (2)the factors that may lead to individual variations in the
endogenous oxytocin system including early life trauma and envi-
ronmental factors (Buisman-Pijlman et al., 2014b). This high-
lights further potential research questions based around whether
attachment difficulties may be in part modifiable not only
through psycho-education and implementation of behavioral
strategies, but through implementation of pharmacotherapies for
high-risk populations.
Furthermore the benefits of intranasal oxytocin administra-
tion in the adult population are now also becoming clearer, and
the potential clinical applications more far-reaching. Researchers
are now investigating the potential use of intranasal oxytocin in
the treatment of depression as an adjunct to selective serotonin
reuptake inhibitors (Emiliano et al., 2007), anxiety (Guastella
et al., 2009), and more recently, anorexia nervosa (Kim et al.,
2014) with promising preliminary results findings. This data
would be of high clinical relevance if translated to trials targeting
the adolescent population in which affective, anxiety and eating
disorders are also prevalent. There are limited animal and human
studies reflecting consistent results to date in pediatric popula-
tions, with the vast majority focusing on the use of intranasal
oxytocin in modifying behaviors related to ASDs. There are
fundamental considerations relating to neuroplasticity, neuro-
adaptation and the impact of significant psychopathology that
remain inadequately explored, and will likely inform further dis-
cussions around the safety of intranasal oxytocin as a therapeutic
intervention. Based on our knowledge of the context-dependent
nature (Guastella and Macleod, 2012), and plasticity of oxy-
tocin system (Buisman-Pijlman et al., 2014b), animal and human
studies are challenging to translate to pediatric populations. In
addition, further questions relating to sensitive and specific meth-
ods of measuring outcomes in potential trials need considera-
tion. Addressing these issues could lead to a broader wealth of
research relating to oxytocin in pediatric populations, findings of
which would likely continue to inform the way in which thera-
peutic interventions in the child and adolescent population are
considered in the future.
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